Norges Bank Makes New $14.43 Million Investment in Grifols, S.A. (NASDAQ:GRFS)

Norges Bank purchased a new stake in shares of Grifols, S.A. (NASDAQ:GRFS) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,940,000 shares of the biotechnology company’s stock, valued at approximately $14,434,000. Norges Bank owned 0.28% of Grifols as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. JPMorgan Chase & Co. raised its stake in Grifols by 144.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock valued at $17,782,000 after purchasing an additional 1,181,959 shares during the period. Helikon Investments Ltd bought a new stake in shares of Grifols during the fourth quarter valued at approximately $580,000. Stifel Financial Corp purchased a new position in shares of Grifols in the third quarter worth $1,043,000. GAMMA Investing LLC boosted its position in shares of Grifols by 44.5% during the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,527 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in Grifols during the third quarter valued at $363,000.

Grifols Stock Performance

NASDAQ GRFS opened at $6.55 on Tuesday. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols, S.A. has a 1-year low of $5.79 and a 1-year high of $9.96. The business has a 50 day simple moving average of $7.52 and a two-hundred day simple moving average of $7.95. The stock has a market capitalization of $4.50 billion, a PE ratio of 5.60 and a beta of 0.41.

Wall Street Analyst Weigh In

Separately, Morgan Stanley assumed coverage on shares of Grifols in a research note on Wednesday, February 12th. They issued an “overweight” rating on the stock.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.